DARA Biosciences (DARA) & Assembly Biosciences (ASMB) Head to Head Analysis
DARA Biosciences (NASDAQ: DARA) and Assembly Biosciences (NASDAQ:ASMB) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, analyst recommendations and risk.
Earnings & Valuation
This table compares DARA Biosciences and Assembly Biosciences’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Assembly Biosciences||$3.04 million||201.23||-$50.92 million||($2.74)||-12.86|
DARA Biosciences has higher revenue, but lower earnings than Assembly Biosciences.
This table compares DARA Biosciences and Assembly Biosciences’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider and Institutional Ownership
72.3% of Assembly Biosciences shares are owned by institutional investors. 19.6% of Assembly Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
This is a summary of recent ratings and recommmendations for DARA Biosciences and Assembly Biosciences, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Assembly Biosciences has a consensus target price of $35.00, indicating a potential downside of 0.65%. Given Assembly Biosciences’ higher possible upside, analysts clearly believe Assembly Biosciences is more favorable than DARA Biosciences.
Assembly Biosciences beats DARA Biosciences on 8 of the 8 factors compared between the two stocks.
About DARA Biosciences
DARA BioSciences Inc is specialty pharmaceutical company based in the United States. The Company’s primary focus is on the commercialization of oncology treatment and oncology supportive care pharmaceutical products, including Soltamox, an oral solution of tamoxifen citrate; cancer support therapeutics, including Gelclair, indicated for the treatment of oral mucositis and Bionect, for the management of irritation of the skin as well as first and second degree burns, and Three Mission Pharmacal products, including Ferralet 90 (for anemia), Binosto (alendronate sodium effervescent tablet indicated for the treatment of osteoporosis) and Aquoral (for cancer related dry mouth). The Company has a clinical development asset, KRN5500, which is a Phase II product candidate targeted for treating cancer patients with painful treatment-refractory chronic chemotherapy induced peripheral neuropathy. The Company is a subsidiary of Midatech Pharma Plc.
About Assembly Biosciences
Assembly Biosciences, Inc. is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome. It has discovered various core protein Allosteric Modulators (CpAMs), which are small molecules that directly target and allosterically modulate the HBV core (HBc) protein. Its Microbiome Program consists of an integrated platform that includes a strain identification and selection process, methods for strain isolation and growth under current good manufacturing practice conditions, and a delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal (GI) tract. The lead product candidate from this platform, AB-M101, is in development for the treatment of clostridium difficile-infections.
Receive News & Stock Ratings for DARA Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DARA Biosciences Inc and related stocks with our FREE daily email newsletter.